Jesus Ovidio Navarro, MD Genesis Clinical Research 4710 N Habana Avenue, Suite 300 Tampa, FL 33614 Phone: 813-873-1016 Fax: 813-879-1336 genclin@aol.com Licenses and Certifications: Florida ME 0057891 DEA BN2374635 Board Certified Internal Medicine, 1992 Board Certified Nephrology, 2006-2016 Memberships: American Society of Nephrology Hillsborough County Medical Association Accomplishments: Low Health-Related Quality of Life Scores in Patients with Anemia and Chronic Kidney Disease J.K. Heifer, W.B. Shapiro, J.O Navarro, J.M. Woolley, J.M. Ford and J. Connolly-Giwa Renal Associates, Little Rock, AR, Brookdale University Hospital and Medical Center, Brooklyn, NY, Genesis Clinical Research, Tampa, FL, Amgen, Inc., Thousand Oaks, CA Chief Administrative Nephrology Fello, 1991-1992, University of Miami, Jackson Memorial Hospital Outstanding third year Internal Medicine Resident, 1989-1990, New York Medical College Metropolitan Hospital Outstanding second year Internal Medicine Resident, 1989-1990, New York Medical Metropolitan Hospital Employment: Genesis Clinical Research Tampa, FL Medical Director and President 10/31/1997 to Present Fresenius Medical Care Tampa, FL Medical Director Kindred Hospital Tampa, FL Chief of Staff 01/01/2013 to Present FMC Carrolwood Tampa, FL Medical Director FMC Ybor Tampa, FL Medical Director
FMC Tampa Tampa, FL Medical Director FMC Brandon Tampa, FL Medical Director Fresenius Medical Care-St. Josephs Acute Dialysis Unit Tampa, FL Medical Director 10/31/1997 to Present Internal Medicine and Nephrology Tampa, FL Medical Director and President 10/31/1997 to Present Florida West Coast Clinical Research Group Tampa, FL Principal and Sub Investigator 07/01/1992 to 10/31/1997 Education: University of Miami Miami, FL Nephrology Fellowship 07/01/1990 to 06/30/1992 New York Medical College-Metropolitan Hospital New York, NY Internal Medicine Resident 07/01/1988 to 06/30/1990 Hahnemann University Philadelphia, PA Medical Intern 06/22/1987 to 06/30/1988 Medical College of Pennsylvania-Frankford Hospital Philadelphia, PA Internal Medicine Resident 07/01/1986 to 06/22/1987 North Shore Medical Center Miami, FL Medical Intern 10/01/1984 to 06/12/1986 University of Miami-Miami Veterans Administration Miami, FL Externships 03/01/1984 to 09/01/1984 Additional courses in Rehabilitative Medicine, Diagnostic Radiology and Psychiatry Universidad CETEC Santa Domingo, Dominican Republic Doctor of Medicine 01/01/1981 to 12/10/1983
Publications: Navarro. J, Serrano, C., Donna, E., and Perez, G.O. Apneic episodes During Bicarbonate Hemodialysis in COPD; Effect of Cuprophane (CU) Versus Polysulfone Membranes. (Abstract presented, ASN meeting 1991). Navarro.J., Oster, J.R., Gkonos, P.J., Ruiz, JP., Rhamy, R.K., & Perez, G.O. Tetany Induced on Separate Occasions by Administration of Potassium and Magnesium in a Patient with Hungry Bone Syndrome. Mineral Electrolyte Metab 1991; 17:340-344. Oster, J.R., Ruiz, J.P., Navarro., Perez, G.O., Clerch, A.R., Cortinas, E.L., and Gold, M.I. Influence of Halothane Hyperbromidemia on Serum Electrolyte and The Anion Gap. Clinical and Toxicology. Ruiz, J.P., Oster, J.R., Navarro., Perez, G.O., Bismo, A.A.L. Low Anion Gap Resulting from Unexplained Exposure to Bromide in a Patient with Renal Amyloidosis, Clinical Toxicology 1992, 30 (4): 663-676 Navarro, J., Perez and Perez, G.O., Apneic Episodes in Non COPD Patients (Abstract presented in Spain, November 1992, Congreso Hispano Americano de Nephrologia.) Research Experience, Principal Investigator: Fibrogen 2015- Present ZSPharma 2014- Present Hyperkalemia (Phase III) Otsuka 2014- Present ADPKD (Phase III) Amgen 2012- Present ND-CKD (Phase III) Novo Nordisk 2014-2014 DMI (Phase III) Astrazeneca 2014-2015 Diabetes II (Phase III) Lilly 2014-2014 DKD/HTN (Phase II) Trevi 2014-2015 Uremic Pruritus (Phase III) Astrazeneca 2014-2014 Hyperphophatemia (Phase II) Amgen 2013-2014 Hyperparathyroidism (Phase II) Akebia 2013-2014 Anemia (Phase II) ZSPharma 2012-2014 Hyperkalemia (Phase III) Otsuka 2012-2014 ADPKD (Phase II) Mitsubishi 2012-2014
Pruritus (Phase II) Sandoz 2012-2015 CKD/ Lilly 2012-2014 DKD/HTN (Phase II) Boehringer 2010 to 2012 CKD in Non-Insulin Patients (Phase III) Boehringer 2010 to 2012 Diabetes/CKD GlaxosmithKline 2010 to 2012 Hypertension (Phase II) Fibrogen 2010 to 2012 Anemia/CKD (Phase II) Forest 2010 to 2011 Johnson & Johnson 2010 to 2011 Type II Diabetes (Phase II) Luitpold 2009 to 2011 Anemia/CKD Amgen/Treat 2004 to 2009 Anemia/CKD Amgen 2008 to 2012 Phosphate Binder/HD (Phase II) Genetech 2007 to 2009 Vascular Access Patency Affy 2008 to 2010 Anemia/HD Affy 2008 to 2010 Anemia/CKD Abbott 2008 to 2009 Hyperparathyroidism/CKD (Phase IV) Abbott 2008 to 2009 Hyperparathyroidism/HD (Phase IV) Select/Post Marketing 2007 to 2012 Phosphate Binder/HD Kremzin 2007 to 2012 CKD NovoNordisk 2007 to 2008 Growth Hormone Evolve 2007 to 2012 Hyperparathyroidism/HD (Phase IV) Amgen 2006 to 2010 Anemia/CKD Johnson & Johnson 2006 to 2007
Anemia/CKD (Phase IV) Luitpold 2005 to 2006 Amgen 2005 to 2006 Hemodialysis/Peritoneal Dialysis (Phase III) Watson Laboratories 2005 to 2006 Iron Deficiency/Dialysis (Phase IV) Advanced Magnetics 2005 to 2005 Iron Deficiency in CRI (Phase III) Ortho Bio-Tech 2005 to 2006 Anemia (Phase II) Advanced Magnetics 2004 to 2005 Iron Deficiency in ESRD (Phase III) Amgen 2004 to 2005 Amgen 2004 to 2009 Anemia/CKD (Phase IV) Amgen 2004 to 2005 Hyperparathyroidism (Phase III) Amgen 2003 to 2005 Hyperparathyroidism (Phase III) Ortho Bio-Tech 2002 to 2005 Ortho Bio-Tech 2002 to 2003 Pfizer 2002 to 2002 Dyslipidemia (Phase IV) Amgen 2002 to 2003 Hemodialysis/Peritoneal Disease (Phase III) Amgen 2002 to 2003 Hemodialysis/Peritoneal Disease (Phase IV) Amgen 2002 to 2003 Hyperparathyroidism in CRI (Phase III) Amgen 2002 to 2003 Anemia Registry (Phase IV) Amgen 2002 to 2003 Anemia Monthly Dosing (Phase IV) Amgen 2002 to 2004 Anemia in Dialysis Population (Phase III) Abbott 2002 to 2002 Hyperparathyroidism (Phase IV) Depomed 2002 to 2002 Diabetes (Phase III)
Glaxosmithkline 2002 to 2003 Glaxosmithkline 2002 to 2003 Diabetes (Phase III) Berlex 2002 to 2003 Hormone Replacement Therapy (Phase III) Bayer 2002 to 2002 Erectile Dysfunction (Phase IV) Ortho Bio-Tech 2001 to 2002 Anemia Registry (Phase IV) Bristol-Myers 2001 to 2002 Luitpold 2001 to 2003 Iron (Phase III) Geltex 2001 to 2003 Phosphate and ESRD (Phase III) Amgen 2001 to 2001 Sleep Disorder (Phase III) Amgen 2001 to 2001 Novartis 2000 to 2001 Solvay 2000 to 2001 Bristol-Myers-Squibb 2000 to 2001 Amgen 2000 to 2001 Anemia and CRI (Phase III) Luitpold 2000 to 2001 IV Iron (Phase III) Amgen 2000 to 2001 Chronic Renal Insufficiency Registry (Phase IV) Amgen 2000 to 2001 Anemia and CRF (Phase III) Bayer 2000 to 2001 Hypercholesterolemia and ESRD (Phase III) Schire Labs 1999 to 2002 Phosporus and ESRD(Phase III) Schein 1999 to 2000 Iron in ESRD (Phase IV) Merck & Co. 1999 to 2000 Hyperlipidemia in High Risk Groups (Phase IV)
BCI 1998 to 1999 Hyperparathyroidism and ESRD Bristol-Myers/Squibb 1997 to 1997 Hypertension Amylin 1997 to 1997 Insulin Dependency Elan/SciRex 1997 to 1997 Hypertension Pfizer 1997 to 1997 Isolated Hypertension Searle 1997 to 1997 Hypertension (Phase II) Searle 1997 to 1997 Elan 1996 to 1997 Merck & Co. 1996 to 1997 Merck & Co. 1996 to 1997 Hypertension and LVH (Phase IV) Bristol-Myers-Squibb 1995 to 1997 Diabetic Neuropathy (Phase III) Parke Davis 1995 to 1997 Acute CVA (Phase III) Smith Kline Beecham 1995 to 1997 Hypertension (Phase II) Amgen 1995 to 1996 CHF/Anemia/ESRD (Phase IV Boeringer Ingelheim 1995 to 1997 Ace Induced Cough (Phase III) Scios Nova 1995 to 1997 Oliguric Acute Renal Failure (Phase III) Boeringer Ingelheim 1995 to 1996 Bristol-Myers-Squibb 1995 to 1996 Hypertension (Phase II) Pfizer 1995 to 1996 Bayer 1995 to 1996 Bristol-Myers-Squibb 1994 to 1996 UPSA 1994 to 1996
UPSA 1994 to 1996 Sankyo/Parexel 1993 to 1997 Amgen 1993 to 1997 Anemia in ESRD (Phase IV) BioPharm/Rorer 1993 to 1996 Pneumonia (Phase III) MSD 1993 to 1996 Renal and sever Hoffman-La Roche 1993 to 1996 Obesity (Phase III) MSD 1993 to 1995 Renal Miles 1993 to 1996 Diabetes (Phase II) Scios Nova 1993 to 1995 Acute Renal Failure(Phase III) Boehringer Mannheim 1993 to 1995 Rhoune-Poulenc-Rorer 1993 to 1994 Pneumonia (Phase III) Rhoune-Poulenc-Rorer 1993 to 1994 Acute Bronchitis (Phase III) Pfizer 1993 to 1994 African Americans and Bio/Pharm/Rore 1993 to 1994 Acute Bronchitis (Phase III) Marrion Merrill Dow 1993 to 1994 Medex 1993 to 1994 Pneumonia (Phase II) Miles 1993 to 1994 Pact 1993 to 1994 Sleep Disorder (Phase IV) Warner Lambert/Parke Davis 1993 to 1993 Diabetes (Phase II) Warner Lambert/Parke Davis 1993 to 1993 Hypertriglyceridemia (Phase II) Nippon Chemiphar 1992 to 1993
Miles 1992 to 1994 MSD 1992 to 1994 Renal and MSD 1992 to 1994 Severe Marion Merrill Dow 1992 to 1993 Knoll Pharmaceuticals 1992 to 1993 Rhone Poulenc-Rorer 1992 to 1993 MSD 1991 to 1994 EM Industries 1991 to 1993